U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA has set a new action date of June 26, 2009 for Takeda's dipeptidyl peptidase IV inhibitor alogliptin, after missing the original user fee deadline of Oct. 27, the company announced Dec. 24
You may also be interested in...
U.S. FDA Clears Takeda Uloric For Gout Indication
Despite concerns about cardiac safety, U.S. FDA approved Takeda's Uloric (febuxostat) for the chronic management of hyperuricemia in patients with gout Feb. 13. The approval marks the first new FDA-approved treatment for gout in more than 40 years
U.S. FDA Clears Takeda Uloric For Gout Indication
Despite concerns about cardiac safety, U.S. FDA approved Takeda's Uloric (febuxostat) for the chronic management of hyperuricemia in patients with gout Feb. 13. The approval marks the first new FDA-approved treatment for gout in more than 40 years
Takeda Readying To Launch Acid Reflux Med Kapidex Within A Month
Japanese drug maker looks to dexlansoprazole to help offset loses when Prevacid and anti-diabetic Actos go off patent this year.